Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q3 2020 Earnings Presentation
17 slides from Marinomed Biotech's earnings presentation, November 2020
Slide 1: Solving the unsolvable with radical innovation
Solving the unsolvable with radical innovation Investor Presentation November 2020 Andreas Grassauer, CEO, Pascal Schmidt, CFO
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Marinomed Q3 Highlights
Marinomed Q3 Highlights Transforming treatments with radical innovation ▪ Carragelose® is in the frontline in combating the current pandemic and those to come ▪ Transforming the entire markets with Marinosolv® - allergic rhinitis market as first target ▪ Record revenues, solid financials and strong
Slide 4: Carragelose – broad band virus blocker
Carragelose® – broad band virus blocker Carragelose® blocks viral attachment to cells via an unspecific physical mechanism 1 2 3 More than 200 respiratory Carragelose® directly binds to Inhibition of attachment of viruses infect the nasal mucosa respiratory viruses and creates viruses to mucosa cell
Slide 5: Carragelose neutralizes SARS-CoV-2
Carragelose® neutralizes SARS-CoV-2 New data from the Friedrich Alexander University in Erlangen, Institute of Virology Carragelose® blocks viral replication at concentrations as low as 5µg/ml. Source: FAU Erlangen, Prof. Ulrich Schubert 5
Slide 6: Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infection
Carrageenan nasal spray may double the rate of recovery from coronavirus* and influenza virus infection Harri Hemilä, University of Helsinki, Elizabeth Chalker, University of Sydney; 16th Nov. 2020 ….carrageenan may also have an effect on the new coronavirus SARS-CoV-2….. Notes: *endemic Coronavirus
Slide 7: SARS-CoV-2 clinical trials with Carragelose
SARS-CoV-2 clinical trials with Carragelose® Study CARR-CoV-02* CHC-20-04 planned Location Argentina Vienna, Austria Vienna, Austria Estimate Enrollment 400 participants 334 participants >300 patients Purpose prevention prevention treatment Medication Nasal spray Nasal/Throat spray Inhalation + Nasa
Slide 8: Marinomed updated Pipeline
Marinomed updated Pipeline PRECLINICAL PHASE I/II PHASE III LAUNCHED 4 Virus-blocking nasal sprays (2 adult / 1 children formulation and 1 decongestant spray) Cough & Cold, Flu-like Illnesses, Respiratory 2 Virus-blocking oral products Applied for marketing 1 Virus-blocking decongestant nasal spray1
Slide 9: Dynamic addressable Allergic Rhinitis (AR) market
Dynamic addressable Allergic Rhinitis (AR) market Intranasal corticosteroid market share increasing1,2 Intranasal corticosteroid market share increasing1,2 7% 3% 38% 15% 47% 12% 2019 2028 USD USD 13.0bn 17.4bn 43% 35% corticosteroids antihistamines immunotherapy other ▪ Standard dose ▪ ~85% reduced
Slide 10: Advanced pipeline of Marinosolv enabled compounds
with advanced pipeline Advanced pipeline of Marinosolv® enabled compounds 1 Nose 3 Ophthalmology Budesolv in allergic rhinitis Tacrosolv in allergic conjunctivitis phase III completed, in registration phase II in 2022* Flutisolv Tacrosolv in dry eyes disease phase III ready phase III in 2022/23* Oth
Slide 11: Upcoming milestones and value inflection points
Upcoming milestones and value inflection points… Preliminary Timetable 2019 H2 ▪ Completion of pivotal Phase-III trial for Budesolv ✓ ▪ Establishment of large-scale production for Budesolv ✓ H1 ▪ Grant for €4m project from FFG for fighting COVID-19 ✓ 2020 ▪ Relocation of 1st part of the company to n
Slide 12: Double digit growth
Double digit growth Solid growth path of Carragelose® Y-o-Y comparison of Revenues (in m€) Healthy Margin +35% +40% +68% +53% 9M 2020 9M 2019 5.1 Sale of goods 4.8 3.0 3.3 Cost of goods sold (3.4) (2.2) 2.8 1.7 Gross result 1.3 0.8 1.3 0.8 1.0 0.9 Gross margin 27.8% 27.8% 12
Slide 13: Significant investments into research and development
Significant investments into research and development COVID-19 and preparations for Marinosolv® studies drive Carragelose® R&D expenses Research and development expenses 9M/20 Change compared to 9M/19 0.5 0.2 0 -0.1 0.0 0.0 -0.5 -0.3 -0.4 -0.7 -1 Personnel Expenses for Depreciation and Total researc
Slide 14: Solid cash position
Solid cash position Flexibility in inventory and cash Inventories Comments Goods for sale Raw materials and supplies ▪ Investment into bottlenecks: glass bottles and 0.1 pumps 0.3 0.5 ▪ Limited unrecognized revenue in Q3/20 0.1 0.2 0.0 FY/19 Q1/20 Q2/20 Q3/20 Cash position ▪ Financial flexibility av
Slide 15: Positive Outlook 2020/21
Positive Outlook 2020/21 Investments in Marinosolv® and commercialisation of Carragelose® Further strong demand for Carragelose® products expected ▪ Lab data and clinical data for Sars-CoV-2 are growth drivers ▪ Full focus on conversion of data into marketing & sales ▪ Ongoing discussions with renow
Slide 16: Stay Healthy! Wash your hands
Stay Healthy! …and further reduce the risk by following these rules + + + Wash Keep Wear Use your hands distance a mask Carragelose® regularly products 16
Slide 17: www.marinomed.com
: Orrarino www.marinomed.com